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by the price reduction (“targeted”) or not (“non-targeted”). We used an interrupted
time series design and segmented regression models to estimate changes in
monthly per capita volume (DDD) and expenditures following the policy. RESULTS:
A total of 72.6% (130/179) of products were targeted by the policy. Biguanides,
sulfonylureas, alpha-glucosidase inhibitors, and thiazolidinediones accounted for
96.8% of oral antidiabetic volume and 93.3% of expenditures. After the policy, there
were reductions in the volume trend (-3.04 DDD/patient/month; 95%CI, [-4.98,
-1.10]) and expenditure trend (-61.76 NT$/patient/month; [-75.00, -48.51]) of tar-
geted medications. Growths in the market volume and expenditures for non-tar-
geted products were stable with no notable changes following the policy. Effects
differed by drug group: use of targeted biguanides remained stable, but expendi-
tures fell by 167 NT$/patient immediately after the policy; use of targeted sulfonyl-
ureas and expenditures also reduced (-2.39 DDD/patient/month [-3.00, -1.78]; 204
NT$/patient immediately after the policy); and use of targeted thiazolidinediones
decreased (-0.58 DDD/patient/month [-0.81, -0.35]). In contrast, use and expendi-
tures for non-targeted biguanides and alpha-glucosidase inhibitors increased,
while non-targeted sulfonylureas remained stable. CONCLUSIONS: Overall, the
price reduction policy resulted in lower use and expenditures for targeted oral
antidiabetics medications, but reductions in market growth for several classes of
targeted products and increases in use of non-targeted products. Our results sug-
gest that the price reduction impacts may differ among specific anti-diabetic drug
groups.
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OBJECTIVES: Individuals with diabetes are particularly susceptible to influenza
and pneumonia infection. They are recommended to receive annual influenza
vaccination during flu season and at least one pneumonia shot during lifetime. The
Healthy People 2010 Initiative set a goal of vaccinating 90% of those diabetic adults
over 65 years old and 60% among diabetic patients less than 65 years of age. Vac-
cination coverage among diabetic adults in the United States, however, is
understudied. METHODS: We analyzed the 2006-2010 National Health Interview
Survey (NHIS) data to 1) estimate the influenza and pneumococcal vaccine cover-
age rates among adults with diabetes over the 5-year study period adjusting for
weights, and 2) identify factors that are potentially associated with both vaccina-
tions among this population using multiple logistic regression. RESULTS: Among
diabetic adults aged 18 to 64 years old, both influenza and pneumonia vaccination
coverage decreased in 2007 and increased steadily from 2008 (weighted estimates:
47.5% for influenza and 32.2% for pneumonia) to 2010 (weighted estimates: 53.4%
for influenza and 38.2% for pneumonia). For those aged 65 years or older, influenza
vaccination coverage was relatively stable from 2006 to 2009 but reduced in 2010.
Pneumonia vaccination rates did not vary much from 2006 to 2010. Overall, both
coverage levels were substantially higher among the aged group. Factors that pos-
itively associated with vaccinationwere 65 years or older, high school education or
above, being married, having a health insurance, formal smoking, longer duration
of being diabetic, having at least one comorbid chronic condition, having more
than 2 physician encounters in last 12 months. CONCLUSIONS: The influenza and
pneumonia vaccination coverage increased marginally among adults with diabe-
tes from 2006 to 2010 but the objective of Health People 2010 had not achieved yet.
Special efforts could be implemented to enhance both vaccine coverage among
diabetic adults.
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OBJECTIVES: Opioid use has grown over the last decade and neuropathy and dia-
betic peripheral neuropathy (DPN) guidelines do not recommend opioids as first
line treatment. This study sought to examine the proportion of DPN patients who
are prescribed opioids and to determine the proportion of DPN patients who are
prescribed opioids as first line treatment.METHODS:A 10% sample of IMS-LifeLink
claims data from 1998 through 2008 were used. The study population consisted of
patients with 1 diagnosis for diabetes and/or 1 claim for an antidiabetic pre-
scription. DPN patients were identified with a validated DPN identification algo-
rithm; and the first date of a DPN diagnosis served as the index date. All patients
were required to have continuous 12 month pre- and post index date plan enroll-
ment and be 17 years of age. Patients with cancer, non-cancer pain conditions,
surgery in the pre- and post- 12 month index period, and with opioid use in the
pre-index period were excluded. Descriptive statistics including demographic
Charlson-comorbidities, with first line use of DPN related medications were
calculated. RESULTS: A total of 984 DPN patients met inclusion exclusion criteria
with a mean age of 60.08 years. 37.40% were female and 29.88% used insulin. 428
DPN patients (43.49%) received DPN pharmacologic treatment. Of those with DPN
pharmacologic treatments, 91 (21.26%) received opioid as first line treatment. An-
tidepressants, anticonvulsants and NSAIDs were initially used by 28.97%, 23.60%,
and 21.96% respectively. The most commonly used opioids were hydrocodone
combinations (8.03%), followed by codeine combinations (2.64%) and oxycodoneCR
(2.44%). Factors associated with opioid use will be reported. CONCLUSIONS: Over
50% of DPN patients remained untreated with pharmacologic therapy after a DPN
diagnosis, which may reflect under-treatment. Despite DPN treatment guidelines
that do not recommend opioids as first line treatment, opioids were among the
most common first line agents used.
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OBJECTIVES: To explore the association between race and the use of Thiazolidin-
ediones (TZDs) and metformin among patients with Type II diabetes in the Mary-
land Medicaid population. METHODS: Medical/prescription/enrollment records
from the Maryland State Medicaid Managed Care Organization/Fee-for-service,
ages 18 or older, initiating use of either metformin or TZDs between 7-1-05 and
12-31-09, followed for 6months. Variations in race over TZDs andmetformin use
are described. Logistic regressions assess the likelihood of 1) starting on TZDs over
metformin, and 2) switching to a TZD given initial use ofmetformin. Models adjust
for other anti-diabetic agents, demographics, and comorbidities: hyptertension
(HTN), hyperlipidemia (HLD), liver disease (LD), renal dysfunction (RD). RESULTS:A
total of 25,758 started on metformin (N19910) or TZDs (N5848). 20% of patients
started on metformin used TZDs later, and 47% of patients started on TZDs used
metformin later. 24% of Caucasians (N8570), 21.5% of African-Americans
(N14094), 22% of Hispanics (N987), and 28.6% of other races (N1,201) were
started on TZDs. 20% of Caucasians started onmetformin switched to TZDs; as did
18% of African-Americans, 22% of Hispanics, and 24% of other races. Logistic re-
gression shows that African-Americans (OR0.88, 95%CI: 0.82-0.95) and Hispanics
(OR0.80, CI: 0.68-0.95) were less likely than Caucasians to be started on TZDs.
Males (OR0.92, CI: 0.86-0.98) were less likely than women, likelihood of initiation
on TZD increases with age or RD (OR1.91, CI: 1.62-2.25), and decreases if HTN
(OR0.64, CI: 0.59-0.69), HLD (OR0.68, CI: 0.62-0.74), or LD (OR0.48, CI: 0.37-0.63)
are present. Therewas no association between race and the likelihood of switching
to TZD once started onmetformin. There was no evidence of sample selection bias
in the lattermodel. CONCLUSIONS:Minority diabetic patients were less likely than
Caucasians to be started on TZDs rather than metformin.
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OBJECTIVES: Compare patient characteristics, medication use, diabetes-related
charges, and resource utilization between patients with Type 2 diabetes (T2DM)
who initiated therapy with an oral fixed combination (OFC) therapy and those
treated with two medications which are available in OFC formulation (dual).
METHODS:Data for this studywere obtained from the i3 inVision™databases over
the time period from January 1, 2006 through June 30, 2010. The analyses compares
patients who initiated therapy on an OFC (N4271) to those who initiated on two
classes of oral medications which are available in an OFC combination (N1780).
Patients were followed for 2 years post initiation and all analyses are descriptive in
nature.RESULTS: Patientswho initiated on anOFC, compared to those treatedwith
dual oral medications, were less likely to be diagnosed with a microvascular
(14.17% vs. 17.02%: p0.0046) or macrovascular (10.68% vs. 14.21%; P0.0001) com-
plication in the pre-period, although they weremore likely to be prescribed an ACE
(11.59 vs. 7.64%; P0.0001), ARB (9.58% vs. 4,44%; P0.0001), or statin (13.28% vs.
10.67%; P0.0001) in the pre-period. Use of OFC, compared to use of dual therapies,
was associated with a significant reduction in post-period hospitalization rates
(15.83% vs. 21.80%; P0.0001) as well as a lower likelihood of an ER visit (2.39% vs.
3.48%; P0.0168) and lower diabetes-related inpatient ($2174 v $3034; P0.0020),
outpatient ($2490 vs. $2,870; P0.0042), drug ($1576 vs. $2084; P0.0001) and total
charges ($6,250 v $8,019; P0.0001). Use of an OFC was associated with a signifi-
cantly higher medication possession ratio (0.58 vs. 0.51; P0.0001) and such pa-
tients were less likely to have a gap in the medication therapy of 60 days or more
(32.76% vs. 37.81%; P0.0002). CONCLUSIONS: The use of an OFC was associated
with improved patient adherence and lower diabetes-related charges compared
the dual cohort.
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OBJECTIVES: To investigate insulin injection treatment patterns and treatment
restrictions, in particular nurse administered insulin injections, on Type 2Diabetes
(T2D) patients receiving care from home healthcare agencies (HHAs), skilled nurs-
ing facilities (SNFs), and veterans affairs (VA) facilities in the United States.
METHODS: Medical directors and other knowledgeable clinical personnel from 67
HHAs, 60 SNFs, and 49 VA facilities completed online surveys in December 2008 to
January 2009 and in December 2010 to January 2011. The VA surveys covered three
VA settings: medical/surgical inpatient (VA-MS), mental health/substance abuse
inpatient (VA-MH/SA), and adult day rehabilitation (VA-ADR). RESULTS:Amajority
(67%) of HHA respondents reported that patients received one injection per day,
while two injections per daywas themost commonly reported number among SNF
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(34%) and VA respondents (VA-MS 34%, MH/SA 27%, VA-ADR 40%). HHA and SNF
respondents reported a similar average maximum number of daily injections per
patient (2.7 and 2.9, respectively). Whereas, almost half of the HHA respondents
reported restrictions on the number of daily nurse-administered injections that
can be delivered (14% also reported that their agencies restricted the types of in-
sulin that nurses can administer), only 10% of the VA-ADR and none of the SNF
respondents reported any restrictions on the number of injections (about 18% of
VA-MS and VA-ADR respondents reported restrictions on the type of insulin).
CONCLUSIONS: Insulin treatment patterns and restrictions on T2D patients vary
across settings, sometime substantially. There is evidence that care, as measured
by nurse administered insulin injections, may be more restricted in home health-
care than in institutional settings such as SNFs and VA facilities.
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OBJECTIVES: Out-of-pocket (OOP) cost as a component of insurance benefit design
has been found to be a barrier to medication adherence or use of preventive care.
This study aimed to assess the association of OOP share of total healthcare expen-
diture (THE) with diabetes monitoring in the United States.METHODS: This cross-
sectional study analyzed the household component data from the 2009 Medical
Expenditure Panel Survey (MEPS). According to the American Diabetes Association
guidelines, proper monitoring was defined as at least two A1c tests along with one
eye or foot examination annually. The OOP share wasmeasured by the percentage
of annual self-paid healthcare expenses out of THE. Insurance coverage was cate-
gorized into any private, public only and uninsured. Logistic regression models
were employed to control for social-demographics, health status, and treatments
among subpopulations with different insurance coverage. Estimates were
weighted to the total population (WTP). RESULTS: Among 2,445 (WTP: 19,780,759)
individuals with diabetes, 66.07% received proper monitoring. Well-monitored in-
dividuals had a lower OOP share (20.10% vs. 26.69%) than those that did not receive
services. Individuals with private insurance, public insurance, and no insurance
reported different OOP share: 21.79%, 15.65%, and 53.30%, respectively. The logistic
regressions indicated that individuals bearing high OOP share were less likely to
receive propermonitoring among individuals with private insurance and no insur-
ance [odds ratio (OR)0.99, 95% confidence interval (95%CI) 0.981-0.999, OR0.98,
95%CI0.975-0.987, respectively]. OOP share was not a significant factor in public
insurance beneficiaries. Other risk factors included older age, race/ethnic minori-
ties, use of oral antihyperglycemic medications and insulin, and worse health
status. CONCLUSIONS: Nearly one-third Americans with diabetes did not receive
proper diabetes monitoring in 2009. The OPP share was inversely associated with
receiving propermonitoring, suggesting the OOP share should be considered in the
benefit design for preventive care, particularly among the privately insured.
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OBJECTIVES: Health care resource utilization and costs may be indicators of dis-
ease severity and overall health status. In observational studies, these factors could
influence patients’ probability of receiving or benefiting from a particular treat-
ment. We compared pre-index utilization and costs in diabetes patients initiating
saxagliptin versus other non-insulin anti-diabetic regimens.METHODS: Individu-
als age 18 years and with evidence of T2DM (ICD-9-CM 250.x0 or 250.x2) were
identified from a US health plan database. Patients with 1 pharmacy claim for
saxagliptin (SAXA) betweenAugust 1, 2009 andDecember 31, 2010were assigned to
the SAXA cohort, and patients with1 pharmacy claim (August 1, 2009-December
31, 2010) for other oral anti-diabeticmedications or GLP-1 analogs were assigned to
the Other cohort. Patients were required to be naive to SAXA or the Other regimen
for 12 months prior to the index pharmacy claim. Utilization and costs were mea-
sured during a 12 month (pre-index) period before treatment initiation. RESULTS:
Pre-index, the SAXA cohort (N4763) had higher rates of all-cause ambulatory
visits (14.7 vs. 13.9; p0.001) and diabetes-related ambulatory visits (5.1 vs. 3.5;
p0.001) versus the Other cohort (N75,943). SAXA patients had higher pre-index
all-cause pharmacy costs ($2808 vs. $1660; p0.001) and diabetes-related total
costs than Other patients ($3683 vs. $2854; p0.001), driven by higher diabetes-
related ambulatory and pharmacy costs (both p0.001). SAXA patients, however,
had lower counts of pre-index all-cause and diabetes-related inpatient visits, all-
cause ED visits, and lower all-cause inpatient and ED costs than the Other cohort.
CONCLUSIONS: In a managed health care setting, pre-index resource utilization
and costs of patients initiating SAXA were higher for ambulatory services and
pharmacy, but ED visits and inpatient stays were lower, compared with patients
initiating other anti-diabetic regimens. These findings suggest SAXA prescribing
patterns could be influenced by differences in patients’ pre-index clinical charac-
teristics and risk profiles, such as difficulty achieving glycemic control in the pre-
index period.
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OBJECTIVES:To estimate the hospitalizations and its costs that can be attributed to
diabetesmellitus (DM) among hospitalizations occurred in Brazilian Public Health-
care System (SUS) between 2008-2010. METHODS: Number of hospitalization and
associated costs for study period was obtained through a review of government
administrative claims database (DATASUS). Hospitalizations with a first-listed di-
agnosis of diabetes were added to hospitalizations estimated to be due to diabetes
by attributable risk methodology (ARM). ARM is based on the formula: RAPi  [P x
(RRi - 1)] / [P x (RRi - 1)1], where RAPi is the fraction of population attributable risk
for medical condition i due to diabetes, P represents prevalence rate of diabetes,
and RRi is the relative risk of medical condition i for people with diabetes com-
pared to those without it (ADA, 2003). Diabetes prevalence was obtained from
VIGITEL-2006, a nationwide random telephonic sample (54,369 individuals). Self-
reported and expanded estimates according to diagnosis rate were used. Relative
risks of hospitalization for chronic complications and general medical conditions
for diabetic subjects were obtained from literature. Results were given for entire
population and per 10,000 inhabitants according to national census bureau.
RESULTS: According to self-reported data, a total of 896,727 hospitalizations were
estimated to be related to DM per year in SUS. This corresponds to 47 hospitaliza-
tions per 10,000 inhabitants annually in the whole population and can reach up to
318,2 per 10,000 when considering the group aged 75. Annual hospitalization
costs were estimated to be Brz$1,167,386,000 or Brz$61,197,90 per 10,000 inhabit-
ants (and Brz$398,058.61/10,000 for 75 population). When considering the expan-
sion of self-reported cases according to diagnosis rate, it was estimate 1,353,161
hospitalizations (70,8 per 10,000) and a total annual cost of Brz$1,778,992 (Brz$
93,140.65/10,000). CONCLUSIONS: DM and its complications are associated with a
relevant economic burden to SUS, especially when considering the elderly popu-
lation.
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OBJECTIVES: To assess the epidemiologic and economic burden of diabetes melli-
tus (DM) from a large population-based study. METHODS: Lombardy Region in-
cludes 9.9 million individuals. Its DM population was identified through a data
warehouse (DENALI), which matches with a probabilistic linkage demographic,
clinical and economic data of different Healthcare Administrative databases. All
individuals who during the year 2000 had an hospital discharge with a IDC-9 CM
code 250.XX, and/or two consecutive prescriptions of drugs for diabetes (ATC code
A10XXXX) within one year, and/or an exemption from co-payment health care
costs specific for DM, were selected and followed up to 9 years. We calculated
prevalence, mortality and health care costs (hospitalizations, drugs and outpatient
examinations/visits) from the National Health Service’s perspective. RESULTS: A
total of 312,223 eligible subjects were identified. The study population (51% male)
had a mean age of 66 (from 0.03 - 105.12) years at the index date. Prevalence was
0.4% among subjects aged 45 years, 3.0% (46-55 years), 7.2% (56-65 years), 11.1%
(66-75 years), 12.2% (76-85 years) and 10.1% (85 years). Overall 43.4 deaths/1,000
patients/year were estimated, significantly (p0.001) higher in men than women.
Overall, 3,315€/patient-year were spent on average: hospitalizations were the cost
driver (54.2% of total cost). Drugs contributed to 31.5%, outpatient claims repre-
sented 14.3% of total costs. As regards hospital costs, 35.6% was attributable to
admissions for cerebro/cardiovascular reasons, 4.3% to admission for DM reasons,
and 60.1% to any other reason. Class C drugs contributed to 33.5% of total drug
costs, 21.8%was attributable to class A (16.7% to class A10) and 4.3% to class B (2.4%
to class B01) drugs. CONCLUSIONS: . Merging different administrative databases
can providewithmany data from large populations observed for long time periods.
DENALI shows to be an efficient instrument to obtain accurate estimates of burden
of diseases such as diabetes mellitus.
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OBJECTIVES:Hospital readmissions are amajor concern for patients with diabetes
in terms of reduced quality of life and increased economic burden. The objective of
the studywas to identify predictors of readmissions among patients with diabetes.
METHODS: A retrospective analysis was conducted using the longitudinal data
from the Medical Expenditure Panel Survey (1999-2009), a set of nationally repre-
sentative surveys of individuals and their health-care providers across the United
States. Patients with a diabetes-related hospital admission during the survey pe-
riod were identified using the International Classification of Disease (ICD)-9 diag-
nosis code, ‘250’. These patients were followed for 12 months to determine if an-
other diabetes-related hospital admission occurred. A logistic regression to predict
readmission was developed and estimated. Covariates included age, gender, race,
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